Apyx Medical (NASDAQ:APYX) Now Covered by Analysts at HC Wainwright

Research analysts at HC Wainwright initiated coverage on shares of Apyx Medical (NASDAQ:APYX) in a research report issued to clients and investors on Monday, Marketbeat Ratings reports. The brokerage set a “buy” rating and a $7.00 price target on the stock. HC Wainwright’s price target suggests a potential upside of 59.82% from the stock’s previous close.

Other research analysts have also issued reports about the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Apyx Medical in a research note on Wednesday, June 24th. Wall Street Zen downgraded shares of Apyx Medical from a “buy” rating to a “hold” rating in a research note on Sunday, April 26th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $6.60.

Apyx Medical Stock Performance

NASDAQ APYX opened at $4.38 on Monday. Apyx Medical has a 12 month low of $1.59 and a 12 month high of $5.08. The company has a current ratio of 5.80, a quick ratio of 4.79 and a debt-to-equity ratio of 2.68. The stock has a 50 day moving average of $4.14 and a 200-day moving average of $3.88. The company has a market cap of $183.57 million, a PE ratio of -19.91 and a beta of 1.37.

Apyx Medical (NASDAQ:APYX) last issued its earnings results on Thursday, May 7th. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.06. Apyx Medical had a negative net margin of 16.40% and a negative return on equity of 88.47%. The business had revenue of $12.49 million for the quarter, compared to the consensus estimate of $10.53 million.

Hedge Funds Weigh In On Apyx Medical

Several institutional investors and hedge funds have recently modified their holdings of APYX. Perkins Capital Management Inc. raised its position in shares of Apyx Medical by 4.9% in the fourth quarter. Perkins Capital Management Inc. now owns 85,000 shares of the company’s stock valued at $298,000 after purchasing an additional 4,000 shares during the period. State Street Corp boosted its holdings in shares of Apyx Medical by 6.8% during the 4th quarter. State Street Corp now owns 116,706 shares of the company’s stock worth $408,000 after buying an additional 7,400 shares during the period. Geode Capital Management LLC grew its stake in Apyx Medical by 2.1% in the 4th quarter. Geode Capital Management LLC now owns 358,829 shares of the company’s stock valued at $1,257,000 after buying an additional 7,551 shares during the last quarter. Silverberg Bernstein Capital Management LLC grew its stake in Apyx Medical by 0.8% in the 1st quarter. Silverberg Bernstein Capital Management LLC now owns 1,041,070 shares of the company’s stock valued at $3,842,000 after buying an additional 8,067 shares during the last quarter. Finally, Nwam LLC bought a new position in Apyx Medical in the 1st quarter valued at about $47,000. 55.33% of the stock is currently owned by institutional investors and hedge funds.

Apyx Medical Company Profile

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.